<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To explore the mechanisms of action of preventive neuroprotection induced by PPAR-alpha activation, we have evaluated the neuronal, vascular effects of preventive treatment with <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> up until the induction of experimental brain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> and <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> treatment withdrawn 3days before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> induction </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> (200mg/kg/day) was administered in rats for 14days or withdrawn 3days before induction of <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Animals underwent a 1-hour middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo), followed by reperfusion for 24h </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:chebi fb="70" ids="34342">MCA</z:chebi>'s vasoreactivity was analyzed and brain sections were used to assess <z:mpath ids='MPATH_124'>infarct</z:mpath> size, inflammatory and <z:mp ids='MP_0003674'>oxidative stress</z:mp> markers </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> administration significantly decreases the cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="5" pm="."><plain>This effect was associated with partial prevention of post-ischaemic <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>However, withdrawal of the <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> treatment 3days before the induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> reduced the neuroprotection and was less beneficial in preventing <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> as well as <z:chebi fb="1" ids="18421">superoxide</z:chebi> <z:chebi fb="5" ids="22563">anion</z:chebi> production </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> significantly reduced microglial activation and neutrophil infiltration into the ischaemic zone to a similar extent in both treatment modes </plain></SENT>
<SENT sid="8" pm="."><plain>Our results show that the <z:chebi fb="0" ids="5001">fenofibrate</z:chebi>-induced cerebral protective effect may be related to both an <z:hpo ids='HP_0011009'>acute</z:hpo> effect and a preconditioning-like mechanism </plain></SENT>
<SENT sid="9" pm="."><plain>The vascular protective effect appears rather to translate the <z:hpo ids='HP_0011009'>acute</z:hpo> effects of <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> administration </plain></SENT>
</text></document>